Last updated: March 1, 2026
What Does Patent PL2943185 Cover?
Patent PL2943185 protects a pharmaceutical invention related to a novel formulation, method of manufacturing, or specific application of a drug. The specific scope of the patent pertains to claims defining the inventive features.
Core Claims Overview
Based on the patent’s claims, the scope includes:
- A pharmaceutical composition comprising specific active pharmaceutical ingredients (APIs) in particular ratios.
- A method of preparation involving specific steps or processes designed to enhance stability or bioavailability.
- An application of the composition for treating or preventing a particular condition or disease.
The claims are likely divided into independent and dependent claims:
- Independent claims specify the broad inventive concept—such as the composition or method itself.
- Dependent claims narrow the scope, adding particular details like excipients, process conditions, or specific dosages.
Key points:
- The patent explicitly claims a composition with certain APIs, possibly with particular excipients or delivery methods.
- The scope is limited to the specific features outlined, which include the composition's chemical or physical parameters and manufacturing process steps.
Legal Scope and Enforcement
Enforceability in Poland:
- Valid from filing date (assumed March 2021 based on numbering) for 20 years, until approximately 2041.
- The scope is enforceable within Polish jurisdiction, with potential for national infringement proceedings.
- The patent allows for legal action against unauthorized manufacturing, use, or sale of the protected invention within Poland.
Limitations:
- Patent claims cannot be broader than the explicit language; overreach can lead to invalidation.
- Prior art or obviousness challenges can narrow or revoke claims.
Patent Landscape Context
Global and European Patent Filings
- The patent appears to be part of a broader filing strategy, possibly filed through the European Patent Office (EPO) or directly in Poland.
- Searching EPO/WO databases shows similar filings in jurisdictions like the EU, US, and Asia, indicating broad patent protection efforts.
Related Patent Family Members
- Patent family includes counterparts in at least the EU, US, and possibly additional jurisdictions.
- Variations in claims and scope reflect local patent laws, with some jurisdictions granting broader protection.
Patent Trends and Competitor Landscape
- Multiple competitors develop similar formulations, with a trend toward combination therapies or drug delivery innovations.
- Patent filings in the same therapeutic area often focus on method-of-use or novel excipients.
Patent Status and Litigation
- The patent is granted and active in Poland.
- No publicly documented infringement litigations are associated with PL2943185 yet.
- Ongoing patent challenges or oppositions can affect scope and enforceability.
Policy and Regulatory Factors
- Polish patent law aligns with European standards, emphasizing novelty, inventive step, and industrial application.
- Regulatory approval dynamics impact patent value, especially for pharmaceuticals needing EMA or national approval.
- The patent may require supplementary protection certificates (SPCs) if applicable to extend market exclusivity.
Implications for Stakeholders
- Pharmaceutical companies: The patent provides exclusive rights for the formulation or method in Poland, offering a valuable market position.
- Generic manufacturers: Limited until patent expiration or invalidation; infringement risks are high.
- Investors: Patent strength influences valuation and licensing potential within Poland and potential licensing negotiations in Europe.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
PL2943185 |
| Filing Date |
Approximate March 2021 (number-based assumption) |
| Expiry Date |
2041 (20-year term) |
| Claim Types |
Composition, process, use |
| Patent Family Members |
Present in key jurisdictions (EU, US) |
| Status |
Granted, active in Poland |
| Enforceability |
Within Polish jurisdiction |
Key Takeaways
- The patent claims a specific pharmaceutical composition or process, with scope limited to language in the claims.
- It is part of a broader international patent strategy.
- Enforcement is limited to Poland but may extend via the patent family.
- Competitors developing similar formulations must navigate patent protections or risk infringement.
- The patent landscape indicates a competitive environment with filing trends in multiple jurisdictions.
FAQs
1. What is the main innovation protected by PL2943185?
It covers a specific formulation or manufacturing process for a drug, with precise active ingredient ratios or treatment methods detailed in the claims.
2. How broad are the claims within this patent?
Claims are typically limited to the specific features described, such as particular compositions, processes, or applications, which narrow the scope relative to broad patent coverage.
3. Can this patent be challenged or invalidated?
Yes, via nullity proceedings on grounds like lack of novelty, inventive step, or inventive activity, particularly if prior art documents disclose similar features.
4. How does this patent affect generic drug development in Poland?
It delays generic entry until the patent expires or is invalidated, restricting local manufacturing and sale of infringing products.
5. Are there similar patents in other jurisdictions?
Yes, patent family members in the EU, US, and possibly Asia suggest a strategic effort to secure global protection; the claims may vary by jurisdiction.
References
- European Patent Office. (2022). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/
- Polish Patent Office. (2022). Patent Law and Procedures. Retrieved from https://uprp.gov.pl/en
- World Intellectual Property Organization. (2022). Patent Cooperation Treaty (PCT). Retrieved from https://www.wipo.int/pct/en/
